Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Net Income (2016 - 2025)

Marimed (MRMD) has disclosed Net Income for 15 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 197.07% to -$2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$17.9 million, a 27.22% decrease, with the full-year FY2024 number at -$12.2 million, up 23.93% from a year prior.
  • Net Income was -$2.9 million for Q3 2025 at Marimed, down from -$1.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $7.6 million in Q2 2021 to a low of -$10.1 million in Q4 2023.
  • A 5-year average of -$871479.4 and a median of -$990000.0 in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: surged 764.97% in 2021, then tumbled 319.5% in 2025.
  • Marimed's Net Income stood at -$6.4 million in 2021, then soared by 174.23% to $4.7 million in 2022, then plummeted by 313.27% to -$10.1 million in 2023, then increased by 18.62% to -$8.2 million in 2024, then skyrocketed by 64.32% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Net Income are -$2.9 million (Q3 2025), -$1.3 million (Q2 2025), and -$5.4 million (Q1 2025).